Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KP-2025

RMP114-mIgG1-D265A

Home » RMP114-mIgG1-D265A

Background of RMP114-mIgG1-D265A

RMP114-mIgG1-D265A is a precision-engineered monoclonal antibody targeting murine PD-1, featuring a D265A mutation in the mIgG1 Fc region to enhance stability and minimize immunogenicity. This variant allows for specific PD-1 inhibition in preclinical models, minimizing off-target effects. Designed for research, RMP114-mIgG1-D265A offers high specificity and purity, suitable for a variety of applications including in vitro and in vivo studies. It serves as a versatile tool for unraveling PD-1 signaling in murine models, supporting the development of novel immunotherapies. In summary, RMP114-mIgG1-D265A provides researchers with a robust and low-immunogenicity alternative for studying PD-1 in immunology and oncology research.

Specifications

Catalog Number:
KP-2025
Antibody Name:
RMP114-mIgG1-D265A
Isotype:
Mouse IgG1, kappa
FC Muations:
D265A
Target:
Mouse PD1
Species Reactivity:
Mouse
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA | FACS| in vivo animal study
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Ribas A. & Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55.
  2. Yamazaki T. et al.,2005. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol. 175(3):1586-92.
  3. Brüggemann M. et al., 1989. The immunogenicity of chimeric antibodies. J. Exp. Med. 170:2153-2157.
  4. Mall C. et al., 2016. Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. Oncoimmunology. 5(2):e1075114.